BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05788601 (Dapiglutide in Obesity): BVCT ex-ante prediction vs. reported outcome

On 15 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 9 Sep 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (superior to tirzepatide).

Clinical Trial

NCTID
NCT05788601
Acronym
DREAM
Drug Name
Dapiglutide
Drug MoA
dual GLP1R/GLP2R agonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Obesity
Human Patients
54
Sponsor
Zealand Pharma
Phase
Phase 1 Phase 2

Prediction of , index 1470

Prospective Prediction
Prediction Index
1470
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit superior to tirzepatide)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
207 days in advance
Readout Data Interpretation
dapiglutide achieved 8.9% placebo-adjusted weight reduction at week 13 vs. 7% placebo-adjusted weight reduction at week 13 achieved by tirzepatide.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (superior to tirzepatide)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial
Phase
Phase 2
Status
Active not recruiting
Enrollment
54
Lead sponsor
University Hospital, Gentofte, Copenhagen
Conditions
Obesity; Inflammation
Interventions
DRUG: Dapiglutide; DRUG: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2023-04-27
Primary completion
2024-04-24
Completion
2025-08-15
Primary outcomes
  • Percentage change in body weight (kg) (From week 0 (baseline) to week 12 (end of treatment))

NCT05788601 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials